Jonathan Rigby, Immune Regulation group CEO

Im­mune Reg­u­la­tion, tak­ing two clin­i­cal pro­grams to 're­set' the im­mune sys­tem, nets $53M+ Se­ries B

A lit­tle un­der two years af­ter a com­pa­ny re­brand­ing, Im­mune Reg­u­la­tion is tak­ing an even big­ger step to­ward ad­vanc­ing its goals.

For­mer­ly known as Peptin­no­vate, the British biotech an­nounced a $53.4 mil­lion Se­ries B ear­ly Mon­day morn­ing, help­ing to fur­ther ad­vance two clin­i­cal pro­grams in rheuma­toid arthri­tis and asth­ma. Though those are the two ini­tial in­di­ca­tions the com­pa­ny is fo­cus­ing on, CEO Jonathan Rig­by told End­points News he hopes the can­di­dates can be ap­plied to a broad swath of au­toim­mune dis­or­ders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.